Sell Merck Stock Ahead Of Its Upcoming Earnings?

Merck (MRK) is set to report earnings on July 29, 2025, with analysts projecting EPS of $2.03 and revenue of $15.87 billion, a year-over-year decline attributed to Gardasil's challenges in China despite strong Keytruda sales. Historically, MRK stock has exhibited a tendency for negative one-day returns post-earnings, declining in 60% of instances over the past five years with a median drop of -2.1%, though positive one-day returns occurred 40-50% of the time. This historical pattern, combined with potential correlations between immediate and medium-term returns, provides key insights for event-driven traders assessing pre-earnings positioning or post-announcement strategies.

Analysis

Merck (MRK) faces a cautious outlook ahead of its July 29, 2025, earnings release, with analyst consensus pointing to a year-over-year decline in both revenue and earnings per share. Projections stand at $15.87 billion in revenue and $2.03 in EPS, compared to $16.11 billion and $2.28 in the prior-year quarter. This anticipated contraction is primarily driven by challenges for its Gardasil vaccine in the Chinese market, which are significant enough to offset the continued sales growth of its flagship oncology drug, Keytruda. Historically, MRK's stock has exhibited a notable negative bias following earnings announcements; over the past five years, the stock has declined on the subsequent trading day in 60% of cases, with a median drop of -2.1%. While more recent data from the last three years shows a more balanced 50% probability of a positive return, the established pattern presents a key data point for event-driven strategies. Despite these short-term headwinds and historical trading patterns, the company maintains a strong fundamental base with a market capitalization of approximately $212 billion and trailing twelve-month net income of $17 billion.

Key Decisions for Investors

• Given the historical tendency for a post-earnings stock decline, investors may consider hedging long positions or exploring short-term bearish strategies, such as buying put options, ahead of the earnings release.
• Investors should scrutinize the earnings report for any updated management guidance on the Gardasil situation in China, as a resolution or worsening of these headwinds will be a primary catalyst for the stock.
• Long-term investors should assess if the expected short-term earnings dip presents a buying opportunity, weighing the current challenges against the company's robust profitability and the ongoing performance of Keytruda.
• Monitor the initial one-day stock reaction post-announcement, as a positive or negative move could signal the medium-term directional trend, offering a potential entry or exit point for tactical positions.